AUPR602401A0 - Sustained release delivery system - Google Patents

Sustained release delivery system

Info

Publication number
AUPR602401A0
AUPR602401A0 AUPR6024A AUPR602401A AUPR602401A0 AU PR602401 A0 AUPR602401 A0 AU PR602401A0 AU PR6024 A AUPR6024 A AU PR6024A AU PR602401 A AUPR602401 A AU PR602401A AU PR602401 A0 AUPR602401 A0 AU PR602401A0
Authority
AU
Australia
Prior art keywords
delivery system
sustained release
release delivery
sustained
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPR6024A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smart Drug Systems Inc
Original Assignee
CASTELLA RES Pty Ltd
CASTELLA RESEARCH Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CASTELLA RES Pty Ltd, CASTELLA RESEARCH Pty Ltd filed Critical CASTELLA RES Pty Ltd
Priority to AUPR6024A priority Critical patent/AUPR602401A0/en
Publication of AUPR602401A0 publication Critical patent/AUPR602401A0/en
Priority to AU2002344686A priority patent/AU2002344686B2/en
Priority to CA2452075A priority patent/CA2452075C/en
Priority to PCT/AU2002/000866 priority patent/WO2003009833A1/en
Priority to CNA028131185A priority patent/CN1536988A/zh
Priority to BR0210630-2A priority patent/BR0210630A/pt
Priority to JP2003515226A priority patent/JP4913321B2/ja
Priority to EP02742516A priority patent/EP1411905A4/en
Priority to NZ529858A priority patent/NZ529858A/en
Priority to US10/482,335 priority patent/US8197839B2/en
Assigned to SMART DRUG SYSTEMS INC reassignment SMART DRUG SYSTEMS INC Assignment by Applicant under S 113 Assignors: Castella Research Pty Ltd
Assigned to SMART DRUG SYSTEMS INC reassignment SMART DRUG SYSTEMS INC Alteration of Name(s) of Applicant(s) under S113 Assignors: Castella Research Pty Ltd
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
AUPR6024A 2001-06-29 2001-06-29 Sustained release delivery system Abandoned AUPR602401A0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AUPR6024A AUPR602401A0 (en) 2001-06-29 2001-06-29 Sustained release delivery system
US10/482,335 US8197839B2 (en) 2001-06-29 2002-07-01 Sustained release delivery system
CNA028131185A CN1536988A (zh) 2001-06-29 2002-07-01 缓释转运系统
CA2452075A CA2452075C (en) 2001-06-29 2002-07-01 Sustained release delivery system
PCT/AU2002/000866 WO2003009833A1 (en) 2001-06-29 2002-07-01 Sustained release delivery system
AU2002344686A AU2002344686B2 (en) 2001-06-29 2002-07-01 Sustained release delivery system
BR0210630-2A BR0210630A (pt) 2001-06-29 2002-07-01 Sistema fornecedor de liberação prolongada
JP2003515226A JP4913321B2 (ja) 2001-06-29 2002-07-01 徐放性医薬組成物
EP02742516A EP1411905A4 (en) 2001-06-29 2002-07-01 DELIVERY SYSTEM WITH DELAYED RELEASE
NZ529858A NZ529858A (en) 2001-06-29 2002-07-01 Sustained release delivery system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR6024A AUPR602401A0 (en) 2001-06-29 2001-06-29 Sustained release delivery system

Publications (1)

Publication Number Publication Date
AUPR602401A0 true AUPR602401A0 (en) 2001-07-26

Family

ID=3829990

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPR6024A Abandoned AUPR602401A0 (en) 2001-06-29 2001-06-29 Sustained release delivery system
AU2002344686A Expired AU2002344686B2 (en) 2001-06-29 2002-07-01 Sustained release delivery system

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002344686A Expired AU2002344686B2 (en) 2001-06-29 2002-07-01 Sustained release delivery system

Country Status (9)

Country Link
US (1) US8197839B2 (enExample)
EP (1) EP1411905A4 (enExample)
JP (1) JP4913321B2 (enExample)
CN (1) CN1536988A (enExample)
AU (2) AUPR602401A0 (enExample)
BR (1) BR0210630A (enExample)
CA (1) CA2452075C (enExample)
NZ (1) NZ529858A (enExample)
WO (1) WO2003009833A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110559431A (zh) * 2019-10-11 2019-12-13 南京农业大学 一种巨型艾美耳球虫纳米亚单位疫苗及其制备方法和应用

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
JP2005505557A (ja) * 2001-09-11 2005-02-24 スマート ドラッグ システムズ インコーポレイティド 持続放出医薬組成物の調製
PT1696822E (pt) * 2003-11-13 2010-04-28 Psivida Inc Implante de libertação controlada injectável com um núcleo de matriz biocorrosível e crosta biocorrosível
US20080044450A1 (en) * 2004-05-31 2008-02-21 Malcolm Brandon Sustained Release Composition
EP2594259A1 (en) 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US20110034498A1 (en) * 2006-03-24 2011-02-10 Mcgovern Karen J Dosing regimens for the treatment of cancer
US20090005869A1 (en) * 2006-12-15 2009-01-01 University Of Virginia Patent Foundation Device which Attaches into a Joint and Carries a Payload of Controlled Release Drugs and Related Method thereof
NZ552290A (en) * 2006-12-21 2009-05-31 Bomac Research Ltd Tablet fomulation
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
EP3190121B1 (en) 2007-12-27 2019-02-20 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction of cyclopamine 4-en-3-one derivative
CA2710377A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Therapeutic cancer treatments
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
US20120130300A1 (en) * 2009-07-14 2012-05-24 Board Of Regents, The Univerity Of Texas System Therapeutic Methods Using Controlled Delivery Devices Having Zero Order Kinetics
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
ITTO20111188A1 (it) 2011-12-22 2013-06-23 Vhit Spa Pompa a cilindrata variabile e metodo di regolazione della sua cilindrata
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
FI20155779A7 (fi) * 2015-10-30 2017-05-01 Solani Therapeutics Ltd Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu
WO2019226519A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
EP3801462A4 (en) 2018-05-24 2022-03-16 Celanese EVA Performance Polymers LLC Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
CA3164309A1 (en) * 2020-01-10 2021-07-15 Samuel D. Waksal Treatment of neurological disorders with avermectins
JP2024515220A (ja) 2021-04-26 2024-04-05 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
CN116687882A (zh) * 2023-07-06 2023-09-05 杭州高成生物营养技术有限公司 一种布洛芬缓释小丸及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4331652A (en) * 1979-09-12 1982-05-25 Eli Lilly And Company Controlled release parasitic formulations and method
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4578075A (en) * 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
EP0205336B1 (en) * 1985-06-11 1991-09-11 Teijin Limited Oral sustained release pharmaceutical preparation
SE444801B (sv) 1985-06-28 1986-05-12 Johan Magnus Ullman Fender
US4786501A (en) * 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US5342622A (en) * 1986-05-16 1994-08-30 The State Of Victoria Subdermal biocompatible implants
JPH01500899A (ja) 1986-05-16 1989-03-30 ザ・ステイト・オブ・ビクトリア 生物適合性インプラント
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
JPH0618958B2 (ja) * 1989-03-08 1994-03-16 株式会社クラレ 多層容器および包装体
ATE90203T1 (de) 1989-03-17 1993-06-15 Pitman Moore Inc Kontrollierte, verzoegerte wirkstofffreisetzung von makromolekularen proteinen.
KR0141583B1 (ko) 1989-06-21 1998-06-15 윌리암 엠. 잭슨 신경병 치료장치
US5091185A (en) 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
EP0542915A1 (en) 1990-08-09 1993-05-26 Endocon, Inc. Multiple drug delivery system
NZ239370A (en) * 1990-08-22 1994-04-27 Merck & Co Inc Bioerodible implantable controlled release dosage form comprising a poly(ortho ester) or a polyacetal with an active agent incorporated into the chain backbone
IS3778A7 (is) 1990-10-31 1992-05-02 Amgen Inc. Aðferð til að gefa dýrum vaxtarhormón, þar sem gefnu magni er stýrt
US5211951A (en) * 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
JPH06321803A (ja) * 1993-05-17 1994-11-22 Kirin Brewery Co Ltd 水溶性ペプチドホルモンの徐放性製剤
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
FR2745180B1 (fr) * 1996-02-23 1998-05-07 Dow Corning Sa Procede de fabrication de dispositifs a liberation controlee
BR9812385A (pt) * 1997-09-23 2000-09-12 Pfizer Formulações parasiticidas
AUPP279698A0 (en) 1998-04-03 1998-04-30 Sunscape Developments Limited Sustained release formulation
IL140899A0 (en) 1998-07-17 2002-02-10 Skyepharma Inc Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof
AU5532699A (en) 1998-09-05 2000-03-27 Seung Jin Lee Biodegradable particulate polymeric preparation and process for producing thereof
US6756048B1 (en) * 1998-09-10 2004-06-29 Sumitomo Pharmaceuticals Company, Limited Long time drug-sustained release preparation
US6645192B2 (en) 1998-09-30 2003-11-11 Ivy Animal Health, Inc. Pellet implant system for immediate and delayed release of antiparasitic drug
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
AU6526100A (en) * 1999-08-06 2001-03-05 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
JP4230621B2 (ja) 1999-08-12 2009-02-25 住友ゴム工業株式会社 空気入りタイヤ
JP4757995B2 (ja) 1999-11-10 2011-08-24 大日本住友製薬株式会社 薬物放出製剤
TW524696B (en) 1999-11-10 2003-03-21 Sumitomo Pharma Sustained-release drug formulations
WO2001037811A1 (en) * 1999-11-22 2001-05-31 Akzo Nobel N.V. Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
JP4504122B2 (ja) 2004-07-02 2010-07-14 株式会社マキタ 生垣バリカン

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110559431A (zh) * 2019-10-11 2019-12-13 南京农业大学 一种巨型艾美耳球虫纳米亚单位疫苗及其制备方法和应用

Also Published As

Publication number Publication date
JP4913321B2 (ja) 2012-04-11
EP1411905A1 (en) 2004-04-28
JP2004535473A (ja) 2004-11-25
WO2003009833A1 (en) 2003-02-06
CN1536988A (zh) 2004-10-13
BR0210630A (pt) 2004-07-27
CA2452075C (en) 2012-08-14
US8197839B2 (en) 2012-06-12
CA2452075A1 (en) 2003-02-06
AU2002344686B2 (en) 2008-07-31
NZ529858A (en) 2006-02-24
US20040247643A1 (en) 2004-12-09
EP1411905A4 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
AUPR602401A0 (en) Sustained release delivery system
AU2002301348A1 (en) Delivery system for cyclopropenes
AU2002323634A1 (en) Flexible delivery system
AU2002325034A1 (en) Stent delivery system
AU2002342073A1 (en) Benefit agent delivery systems
AU2002326933A1 (en) Plasmatron-catalyst system
AU2001283359A1 (en) Drug release (delivery system)
AU2002343555A1 (en) Eutectic-based self-nanoemulsified drug delivery system
AU2002345340A1 (en) Magneto-massage system
AUPR951501A0 (en) Modified sustained release pharmaceutical system
AU2002210894A1 (en) Sustained release delivery system and uses thereof
AU2002337595A1 (en) Anastomotic delivery system
AUPR434401A0 (en) Fuel delivery system
AU2002222138A1 (en) Drug delivery system
AU2002210580A1 (en) Drug delivery system
AU2002351380A1 (en) Bookview system
AU2001238040A1 (en) Offer delivery system
GB0113857D0 (en) Delivery system
AU2002216843A1 (en) Delivery systems
AU2002251245A1 (en) Lectin-directed prodrug delivery system
AUPQ616800A0 (en) Secure delivery system
AU2002342072A1 (en) Controlled benefit agent delivery system
AU2002315368A1 (en) User-activatible substance delivery system
HK1065475A (en) Drug delivery system
AUPR877101A0 (en) Transdermal delivery system

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SMART DRUG SYSTEMS INC

Free format text: THE FORMER OWNER WAS: CASTELLA RESEARCH PTY LTD